Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.

Summary: Catalent has made significant investments in the cell and gene therapy space with strategic acquisitions and commitment to grow and innovate.

Summary: Catalent has made significant investments in capacity expansions to meet the growing demand of our customers.

Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.

Summary: In a panel discussion executives from Moderna, Sanofi Pasteur, Takeda and Catalent share behind-the-scenes updates on their respective efforts to develop a COVID-19 vaccine.

Summary: Catalent offers tools to measure the ratio and help assess the safety and efficacy of viral vector-based therapies.

Summary: In this webinar, experts discuss new cell line development methodologies, including new instrumentation, for clinical and commercial programs.

Summary: Our panel of experts from Humanigen, Catalent and WYSS Institute discuss the challenges of advancing a repurposed drug to market and how to overcome them to achieve strategic success

Summary: This executive summary details why maintaining a strategic view of the production-scale from early stages of development helps accelerate the time-to-market, drives process efficiencies, and reduces costs.

Summary: In this webinar, hear from Catalent panelists as they discuss navigating the path from research lab to the clinic.